• Decoy Therapeutics will hold a virtual special shareholder meeting on Sept. 14, 2026.
• Vote set on allowing exercise of Series A, Series B, Series C common warrants from a June 2026 private placement, enabling issuance of up to 2,961,085 shares.
• Shareholders will also consider cutting authorized common shares by 10,000,000 to 90,000,000.
• Proposal includes authority to adjourn the meeting to solicit additional proxies if needed to pass the warrant or authorized share items.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Decoy Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-316072), on July 24, 2026, and is solely responsible for the information contained therein.